Scott McMeekin - Concepedia

Author

Scott McMeekin

University of Oklahoma Health Sciences Center

Also Known As

S MCMEEKIN, S McMeekin, S. D. McMeekin, S. McMeekin, S. Mcmeekin, SCOTT MCMEEKIN, Scott D McMeekin, Scott D. McMeekin, Scott McMeekin

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

University of Oklahoma Health Sciences Center University of Oklahoma Massachusetts General Hospital University of California, Irvine Fox Chase Cancer Center

About

Scott McMeekin is an author at University of Oklahoma Health Sciences Center specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.2K
2	Health Sciences	3	3	83
3	Public Health	2	2	59
4	Engineering	1	1	30
5	Natural Sciences	1	1	49

Scott McMeekin

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer David G. Mutch, Mauro Orlando, T. Goss, Journal of Clinical Oncology	2007	432
Extraovarian Peritoneal Serous Papillary Carcinoma: A Case-Control Retrospective Comparison to Papillary Adenocarcinoma of the Ovary Jeffrey D. Bloss, Shu‐Yuan Liao, Richard E. Buller, Gynecologic Oncology Surgical OncologyTumoral PathologyGynecological SurgeryGynecologySurgery	1993	266
MICU1 drives glycolysis and chemoresistance in ovarian cancer Prabir K. Chakraborty, Soumyajit Banerjee Mustafi, Xunhao Xiong, Nature Communications	2017	170
Surgical Management of Early-Stage Endometrial Cancer in the Elderly: Is Laparoscopy Feasible? Dennis R. Scribner, Joan L. Walker, Gary A. Johnson, Gynecologic Oncology Gynecologic SurgeryLaparoscopySurgical OncologyGynecological SurgeryMinimally Invasive Procedure	2001	157
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma Ursula A. Matulonis, Ignace Vergote, Floor Backes, Gynecologic Oncology Tumoral PathologyMedicineGynecologyPathologyPhase Ii Study	2014	118
Characteristics of 10-year survivors of high-grade serous ovarian carcinoma Fanny Dao, Brooke A. Schlappe, Jill Tseng, Gynecologic Oncology	2016	107
A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer N. Colombo, Scott McMeekin, Peter E. Schwartz, Journal of Clinical Oncology Advanced Endometrial CancerSingle AgentProgressive Endometrial CancerMedicineCancer Management	2007	100
Laparoscopic Pelvic and Paraaortic Lymph Node Dissection: Analysis of the First 100 Cases Dennis R. Scribner, Joan L. Walker, Gary A. Johnson, Gynecologic Oncology LaparoscopyMinimally Invasive ProcedureLaparoscopic PelvicSurgical PathologyPelvic Reconstructive Surgery	2001	99
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer Scott McMeekin, Don S. Dizon, James Barter, Gynecologic Oncology Advanced Endometrial CancerMedicinePhase IiiGynecologyPharmacotherapy	2015	76
Bowel Resection at The Time of Primary Cytoreduction for Epithelial Ovarian Cancer Noelle Gillette-Cloven, Robert A. Burger, Bradley J. Monk, Journal of the American College of Surgeons	2001	76

Page 1